Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.

SHR-1701 will be administered by IV, 1200mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Famitinib will be administered at 15 mg orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. SHR-1701 plus famitinib will be administered 1-3 days after cryoablation.